Case Study
Introduction: In 2021, a biotech company was developing a vaccine that needed large scale oligonucleotide production capacity and rapid turnaround to produce hundreds of kilo oligonucleotide…
Introduction: In 2021, a biotech company was developing a vaccine that needed large scale oligonucleotide production capacity and rapid turnaround to produce hundreds of kilo oligonucleotide adjuvant. From May 2021 to September 2022, in 16 months with COVID interruptions, WuXi TIDES completed the technology transfer and delivered over 400kg of oligonucleotide product, as well as Process Performance Qualification (PPQ) enabling and PPQ campaign. Moreover, WuXi TIDES developed a robust commercial supply chain to support large-scale oligonucleotide manufacturing.
Keep reading
Process mass intensity (PMI) is one of the most important metrics in sustainable manufacturing. It measures the total mass of raw materials required to produce a given mass of product. In…
As GLP-1 receptor agonists continue to redefine treatment for metabolic diseases, drug developers are racing to bring new and more complex therapies to the clinic. But innovation alone is…
A new publication by MSD in Organic Process Research & Development details the process development and large-scale manufacturing of the key Northern Fragment of Enlicitide Decanoate.
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA